ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
If you are not happy with the results below please do another search
WuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics’ WuXiBody platform.
PHARMAP 2025 brings together experts from all over the world in Berlin, Germany on 14-15 April to share how to make medicine smarter and safer. Leading pharmaceutical companies from the EU, Asia, North America, the Middle East, Africa and others participate in the Congress to find new contacts and expand their network.
Nippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency.
The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.